One of the first attempts to establish the role of TP53 mutations in this subset of patients was performed by Molina-Vila and colleagues, who explored the prognosis of 125 wild-type (wt) EGFR and 193 (training cohort) and 64 (validation cohort) mutated EGFR NSCLC patients. The gene discussed is TP53; the disease is non-small cell lung carcinoma.